GlassScriptPhysician profile
Vanessa P Cox
NPI 1912528001
$10,280.23
in general payments reported to CMS, 2019-2025
35 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,175 · 2022: $2,102 · 2023: $2,181 · 2024: $2,065 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,930 · Education: $73.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,929.78 |
| Education | $73.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,335.48 | 2021-2025 | Breztri, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,371.36 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,120.52 | 2021-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $860.04 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $625.43 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $606.36 | 2021-2024 | Yupelri |
| Grifols USA, LLC | $394.09 | 2021-2024 | Prolastin-C Liquid |
| Amgen INC. | $299.82 | 2022-2025 | Tezspire |
| Csl Behring | $294.47 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $293.50 | 2021-2025 | Cuvitru, Hyqvia, Glassia |
| Insmed, INC. | $287.92 | 2021-2024 | Arikayce |
| Electromed, INC. | $287.90 | 2021-2024 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $286.39 | 2021-2023 | Uptravi, Opsumit |
| Teva Pharmaceuticals USA, INC. | $211.86 | 2021-2023 | Airduo Digihaler |
| Octapharma USA, INC. | $128.95 | 2024-2025 | Panzyga |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $111.97 | 2022-2025 | Nuzyra, Xhance |
| Blueprint Medicines Corporation | $107.06 | 2024-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $90.69 | 2025 | |
| Optinose US, INC. | $86.39 | 2024-2025 | |
| Verona Pharma, INC. | $66.92 | 2025 | Ohtuvayre |
| Galderma Laboratories, L.P. | $43.30 | 2025 | Nemluvio |
| Lilly USA, LLC | $40.51 | 2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $35.79 | 2025 | Dawnzera |
| Sunovion Pharmaceuticals INC. | $34.96 | 2021 | |
| Mallinckrodt Hospital Products INC. | $33.08 | 2021 | |
| Pfizer INC. | $32.76 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $32.48 | 2022 | |
| United Therapeutics Corporation | $30.97 | 2022-2024 | Tyvaso |
| X4 Pharmaceuticals, INC. | $26.62 | 2025 | Xolremdi |
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2023 | |
| Boston Scientific Corporation | $19.90 | 2023 | |
| Hikma Pharmaceuticals USA | $19.30 | 2024 | Ryaltris |
| Abbvie INC. | $15.82 | 2025 | |
| Covis Pharma Gmbh | $14.36 | 2022 | |
| Mayne Pharma Commercial LLC | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.